Obesity Drug Stocks: Why It Will Be ‘Exceptionally …

Obesity Drugs: Can New Firms Take Market Share From Eli ... - MorningstarObesity Drug Stocks: Where to Invest Now - Morningstar

CouponFollow Extension

$144
OFF

Pharma Stocks: 10 To Watch In The Blistering Weight-Loss Drugs …

4 weeks from now

Aug 30, 2024 · The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could cash in, rivaling kingpins Novo Nordisk and Eli Lilly.

investors.com

9%
OFF

Novo, Lilly Shares Rise As Biden Proposes Obesity Care Coverage

4 weeks from now

4 days ago · Biden proposes expanding coverage for anti-obesity drugs Novo shares jump as much as 4.9%, Lilly stock also gains Amgen weight-loss drug trial results miss market …

reuters.com

4%
OFF

LLY, NVO Stock Up As Biden Proposes Medicare Cover For Obesity …

4 weeks from now

3 days ago · Year to date, Lilly’s stock has risen 35.4% and Novo Nordisk has gained 2.6% compared with an increase of 6.3% for the industry. ... Why Should LLY’s & NVO’s Obesity …

nasdaq.com

15%
OFF

Weight-loss Stocks Soar On Obesity Drug Study Results - Fortune

4 weeks from now

Aug 8, 2023 · Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a ‘huge win’ for future sales. BY Angel Adegbesan, Jameelah Robinson and …

fortune.com

$67
OFF

Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says

4 weeks from now

Consensus sales for obesity drugs already approved and in development are expected to reach ~$67B. Meanwhile, obesity sales are expected to exceed IO in 2029 before reaching a similar …

nasdaq.com

80%
OFF

This Overlooked Obesity-drug Stock Has 80% Upside, JPMorgan Says

4 weeks from now

May 22, 2024 · Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. JPMorgan initiated the company at "Overweight" with a $65 price target, …

yahoo.com

FAQs about Obesity Drug Stocks: Why It Will Be ‘Exceptionally … Coupon?

Will the global market for obesity drugs increase by 15-fold?

The global market for the blockbuster drugs could increase by 15-fold over the next five years as their benefits expand beyond weight loss, with expected implications for consumer goods and longevity. The global market for obesity drugs could increase by more than 15-fold by 2030 as their use expands beyond weight loss to treat a range of diseases. ...

Is there a market for obesity drug makers?

There's certainly a market for what obesity drug makers are offering. The U.S. Centers for Disease Control and Prevention reports that 2 in 5 U.S. adults have obesity. The numbers are sobering: 41.9% of U.S. adults are considered obese, and 9.2% are considered highly obese. ...

Will next-generation obesity drugs disrupt the market?

Over the next three to four years, we expect substantial disruption from next-generation obesity drugs by Roche RHHBY, Amgen AMGN, Pfizer PFE, AstraZeneca AZN, private firm Boehringer, and acquisition targets including Viking and Structure. These drugs will likely take market share and pressure drug pricing. ...

How many new obesity drugs will come out by 2029?

We expect 16 new obesity drugs could launch by 2029, with roughly $70 billion of the GLP-1 market coming from these challengers by 2031. That said, Novo and Lilly are also advancing their next-generation pipelines, beginning with Novo’s cagrisema and Lilly’s orforglipron in 2026. ...

Should you buy weight loss drug stocks?

Keep an eye on these stocks as the weight loss drug market stabilizes and Uncle Sam steps into the pricing picture. Weight loss drugs show promising results for overweight Americans, which bodes well for sector stocks. Wall Street analysts can barely keep up with the pace of the diabetes and weight loss drug markets – and for good reason. ...

Which big pharma companies are gaining traction with their own obesity drugs?

Other Big Pharma companies looking to gain traction with their own obesity drugs include Roche RHHBY, Pfizer PFE, and Amgen AMGN. Amid the obesity epidemic in the United States, for years, pharmaceutical companies have been attempting to develop effective treatments. ...